This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lattice Biologics (LBL) Stock Overview

A biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. More details

LBL fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Shares are highly illiquid

Does not have a meaningful market cap (CA$128)

LBL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Lattice Biologics Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lattice Biologics
Historical stock prices
Current Share Price	US$0.04
52 Week High	US$0.04
52 Week Low	US$0.04
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	100.00%
Change since IPO	-88.24%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	LBL	CA Biotechs	CA Market
7D	n/a	0.4%	0.6%
1Y	n/a	5.1%	19.3%

Return vs Industry: Insufficient data to determine how LBL performed against the Canadian Biotechs industry.

Return vs Market: Insufficient data to determine how LBL performed against the Canadian Market.

Price Volatility

Is LBL's price volatile compared to industry and market?
LBL volatility
LBL Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.1%
Market Average Movement	9.2%
10% most volatile stocks in CA Market	18.2%
10% least volatile stocks in CA Market	3.6%

Stable Share Price: LBL has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LBL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Guy Cook	n/a

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; and acellular dermal matrix that provides a natural collagen tissue scaffold that promotes cellular ingrowth, tissue vascularization, and regeneration The company also develops amniotic fluid-based products, such as AmnioBoost and AmnioBlast. In addition, it sells traditional allografts for multi-disciplinary applications, including orthopedics, neurology, podiatry, and oral/maxillofacial.

Lattice Biologics Ltd. Fundamentals Summary

How do Lattice Biologics's earnings and revenue compare to its market cap?
LBL fundamental statistics
Market cap	CA$175.12
Earnings (TTM)	-CA$1.30m
Revenue (TTM)	CA$2.13m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is LBL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LBL income statement (TTM)
Revenue	US$1.56m
Cost of Revenue	US$912.36k
Gross Profit	US$645.64k
Other Expenses	US$1.60m
Earnings	-US$951.65k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did LBL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/07/16 12:46
End of Day Share Price	2024/07/15 00:00
Earnings	2021/06/30
Annual Earnings	2020/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lattice Biologics Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Siddharth Rajeev	Fundamental Research Corp.